2022 World Conference on Lung Cancer (ePosters)-EP08.02-054. Efficacy and Safety of TKI Dose Reduction

Pdf Summary

This study aimed to evaluate the efficacy and safety of reduced doses of tyrosine kinase inhibitors (TKIs) in the treatment of lung cancer. TKIs are targeted therapies that can be individually tailored for patients with non-small cell lung cancer (NSCLC), resulting in fewer side effects compared to chemotherapy. However, TKIs can still cause adverse effects, and dose reduction may be considered to improve tolerability.<br /><br />The study involved a retrospective analysis of patients receiving oral TKIs for lung cancer between 2018 and 2021. Patients who did not start the treatment were excluded. The sample was divided into two groups based on the treatment dose: a reduced dose group and a full dose group. The primary endpoint was to determine if the use of reduced doses of TKIs could achieve similar therapeutic outcomes as the standard dose.<br /><br />The results showed that there was no significant difference in overall survival or progression-free survival between patients treated with the full dose and those treated with a reduced dose of TKIs. Although these findings may not be sufficient to identify which patients would benefit from dose reduction, they suggest that reduced doses of TKIs may still be effective while being better tolerated.<br /><br />The study included patients with different types of lung cancer, including adenocarcinoma, squamous cell carcinoma, and pleomorphic carcinoma. It also assessed the presence of specific gene mutations, such as EGFR, ALK, ROS, MET, and BRAF. The study reported the percentage of patients with each mutation in each treatment group.<br /><br />Regarding toxicity, the study found that patients in the reduced dose group experienced fewer adverse effects compared to those in the full dose group. The most common toxicities observed included cardiovascular, gastrointestinal, hepatic, renal, dermatologic, hematologic, and endocrine toxicities.<br /><br />The study concludes that further research is needed to establish the role of reduced doses of TKIs in the treatment of lung cancer. While the study suggests that reduced doses may be effective and better tolerated, it does not provide enough evidence to make definitive recommendations.

Asset Subtitle

Fernando Pereira da Silva

Meta Tag

Speaker Fernando Pereira da Silva

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

tyrosine kinase inhibitors

lung cancer treatment

NSCLC

chemotherapy alternative

dose reduction

therapeutic outcomes

overall survival

progression-free survival

gene mutations

toxicities